Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.
Applied BioMath applies biosimulation, including quantitative systems pharmacology, PKPD, bioinformatics, machine learning, clinical pharmacology, and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through all phases of clinical trials.
Tristar Technology Group
Breast and Lung cancer are important diseases for antibody drug conjugate (ADC) therapeutic development with several approved in both diseases. Tristar ran approved IHC assays for HER2 and PD-L1 and optimized IHC assays for TROP2, NECTIN-4, B7-H3, and B7-H4 on serial slides from tissue microarrays for breast (hormone receptor positive and triple negative breast cancer) and lung cancer (adeno and squamous subtypes). Pathologists scored each target on the plasma membrane using approved methods for HER2 and PD-L1 and histoscores for other ADC targets. Summary data for prevalence of each target will be presented. The data may help inform where these ADC targets are highest expressed, where they overlap with respect to each other, and how expression correlates to standard of care outcomes data and their potential for combining with immunotherapies.
BPS Bioscience's purpose is to advance new scientific discoveries that lead to therapies by creating innovative solutions for research. Our focus areas are immunotherapy, epigenetics, coronavirus, CRISPR, cell signaling, and others, providing 4000+ high-quality recombinant cell lines, lentiviruses, proteins and all aspects of biochemical and cell-based assay development. As a primary manufacturer, we can supply products in large-scale bulk quantities, as well as contract and custom manufacturing. Our biochemical and cell-based screening services are also available to accelerate your research.
Navigo Proteins is a successful and steadily growing, privately held protein engineering company, which develops best-in-class custom precision affinity ligands, based on selected protein scaffolds. We partner with pharma, biotech and life science companies to build innovative biotherapeutics as well as provide next-generation custom affinity solutions for commercial biologics manufacturing based on our proprietary affinity ligands. Our outstanding protein engineering capabilities rely on our dedicated specialist team with in-depth expertise and a strong track record. Our combined know-how is complemented by a state-of-the-art technology toolbox, including robotics-assisted selection and screening technology platforms.